L-type calcium channel blocker increases VEGF concentrations in retinal cells and human serum.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Vascular Endothelial Growth Factor A*/metabolism ; Diabetic Retinopathy*/metabolism; Adult ; Humans ; Calcium Channel Blockers/pharmacology ; Calcium Channel Blockers/therapeutic use ; Antihypertensive Agents/therapeutic use ; Amlodipine/pharmacology
    • Abstract:
      Objective: Vascular endothelial growth factor (VEGF) plays a key role in diabetic retinopathy (DR). Previously, we have reported an association between mutations in a gene coding for the L-type calcium channel subunit, VEGF and DR. L-type calcium channel blockers (LTCCBs) have been widely used as antihypertensive medication (AHM), but their association with VEGF and DR is still unclear. Therefore, we explored the effect of LTCCBs compared to other AHMs on VEGF concentrations in retinal cells and human serum. Furthermore, we evaluated the association between the use of LTCCBs and the risk of severe diabetic eye disease (SDED).
      Research Design and Methods: Müller cells (MIO-M1) were cultured as per recommended protocol and treated with LTCCBs and other AHMs. VEGF secreted from cells were collected at 24 hours intervals. In an interventional study, 39 individuals received LTCCBs or other AHM for four weeks with a four-week wash-out placebo period between treatments. VEGF was measured during the medication and placebo periods. Finally, we evaluated the risk of SDED associated with LTCCB usage in 192 individuals from the FinnDiane Study in an observational setting.
      Results: In the cell cultures, the medium VEGF concentration increased time-dependently after amlodipine (P<0.01) treatment, but not after losartan (P>0.01), or lisinopril (P>0.01). Amlodipine, but no other AHM, increased the serum VEGF concentration (P<0.05) during the interventional clinical study. The usage of LTCCB was not associated with the risk of SDED in the observational study.
      Conclusions: LTCCB increases VEGF concentrations in retinal cells and human serum. However, the usage of LTCCBs does not appear to be associated with SDED in adults with type 1 diabetes.
      Competing Interests: EBP reports receiving lecture honorariums from Eli Lilly, Abbott, Astra Zeneca, Sanofi, Boehringer Ingelheim and is an advisory board member of Sanofi. PHG reports receiving lecture honorariums from Astellas, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Elo Water, Medscape, MSD, Mundipharma, Novo Nordisk, PeerVoice, Sanofi, Sciarc, and being an advisory board member of Astellas, Astra Zeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Janssen, Medscape, MSD, Mundipharma, Novo Nordisk, and Sanofi. This does not alter our adherence to PLOS ONE policies on sharing data and materials. AK, SM, TH, VH, RL, SiMa, CF, ML and KK declare no conflict of interest.
      (Copyright: © 2023 Kumar et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
    • References:
      Cardiol Res. 2014 Oct;5(5):145-150. (PMID: 28348712)
      Eur Heart J. 2020 Jan 7;41(2):255-323. (PMID: 31497854)
      Ophthalmol Retina. 2019 Jun;3(6):473-477. (PMID: 31174668)
      Cochrane Database Syst Rev. 2015 Jan 31;1:CD006127. (PMID: 25637717)
      Diabetes Care. 2014 Apr;37(4):893-9. (PMID: 24652720)
      Handb Exp Pharmacol. 2017;242:31-55. (PMID: 27787714)
      Stem Cells. 2007 Aug;25(8):2033-43. (PMID: 17525239)
      Clin Ophthalmol. 2012;6:185-91. (PMID: 22331976)
      Invest Ophthalmol Vis Sci. 2017 Jun 1;58(7):2915-2921. (PMID: 28586916)
      Hypertens Res. 2005 Feb;28(2):147-53. (PMID: 16025742)
      PLoS One. 2014 Oct 16;9(10):e110531. (PMID: 25329921)
      Diabetes Care. 2005 Aug;28(8):2019-24. (PMID: 16043748)
      Diabetes. 2019 Nov;68(11):2165-2174. (PMID: 31439644)
      Diabetologia. 2018 Dec;61(12):2654-2667. (PMID: 30112688)
      Diabetes Metab J. 2018 Oct;42(5):364-376. (PMID: 30362302)
      Am J Hypertens. 2007 Mar;20(3):311-8. (PMID: 17324745)
      Glia. 2019 Feb;67(2):321-331. (PMID: 30444022)
      Ann Intern Med. 2018 May 1;168(9):640-650. (PMID: 29610837)
      Hypertension. 2020 Jun;75(6):1334-1357. (PMID: 32370572)
      Prog Retin Eye Res. 2003 Jan;22(1):1-29. (PMID: 12597922)
      Lancet Diabetes Endocrinol. 2015 Apr;3(4):263-74. (PMID: 25660574)
      Diabetes Care. 2012 Mar;35(3):556-64. (PMID: 22301125)
      Diabetologia. 2018 May;61(5):1203-1211. (PMID: 29423580)
    • Accession Number:
      0 (Vascular Endothelial Growth Factor A)
      0 (Calcium Channel Blockers)
      0 (Antihypertensive Agents)
      1J444QC288 (Amlodipine)
    • Publication Date:
      Date Created: 20230413 Date Completed: 20230417 Latest Revision: 20230419
    • Publication Date:
      20231215
    • Accession Number:
      PMC10101440
    • Accession Number:
      10.1371/journal.pone.0284364
    • Accession Number:
      37053203